Here are the 10-Q quarterly reports from Lixte Biotechnology Holdings, Inc. Warrants (LIXTW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LIXTW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIXTW filings page.
Lixte Biotechnology Holdings reported a larger quarterly loss as it continues to advance its cancer drug and proton therapy programs without generating revenue. For the three months ended March 31, 2026, the company recorded a net loss of $1.99 million, compared with $0.71 million a year earlier, driven mainly by higher general and administrative costs of $1.65 million and research and development spending of $0.33 million. Cash declined to $3.25 million from $5.11 million at December 31, 2025, and management concluded there is substantial doubt about its ability to continue as a going concern without additional financing. The balance sheet now includes the LiGHT proton therapy system at a carrying value of $6.61 million and a related operating lease liability of $1.06 million, reflecting the 2025 acquisition of Liora Technologies Europe Ltd. All Series B Convertible Preferred Stock was converted into common stock, increasing shares outstanding to 11.63 million at March 31, 2026. Lixte remains focused on clinical trials of its lead compound LB‑100 and on recommissioning the LiGHT system, while noting it must raise additional capital to fund planned clinical and proton therapy activities.